William C Temple

5PUBLICATIONS
15CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Dec 30, 2025
Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.

Adila Izgutdina, Tasfia Rashid, William C Temple

|Apr 23, 2025
Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia.

Juwita Werner, Alex G Lee, Chujing Zhang

|Nov 25, 2023
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies.

William C Temple, Matthew A Nix, Akul Naik

|Nov 07, 2023
Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patients.

Savannah S Shumock, William C Temple, Amanda Marinoff

|Dec 14, 2020
Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma.

William C Temple, Kieuhoa T Vo, Katherine K Matthay

Pageof 1

Frequent Collaborators

2 joint publications

Elliot Stieglitz

2 joint publications

Adila Izgutdina

2 joint publications

Arun P Wiita

1 joint publications

Savannah S Shumock